{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:27:46Z","timestamp":1762658866655},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.gtc.2004.02.010","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T14:53:30Z","timestamp":1113836010000},"page":"303-317","source":"Crossref","is-referenced-by-count":16,"title":["Mesalamine derivatives in the treatment of Crohn's disease"],"prefix":"10.1016","volume":"33","author":[{"given":"Laura E","family":"Harrell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B","family":"Hanauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2004.02.010_BIB1","first-page":"497","article-title":"Sulfasalazine: II. Some notes on the discovery and development of salazopyrin","volume":"83","author":"Svartz","year":"1988","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB2","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(77)90831-5","article-title":"An experiment to determine the active therapeutic moiety of sulphasalazine","volume":"2","author":"Azad Khan","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2004.02.010_BIB3","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2125.1983.tb02254.x","article-title":"Kinetics of 5-aminosalicylic acid after jejunal instillation in man","volume":"16","author":"Haagen Nielsen","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/gut.28.2.196","article-title":"Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract","volume":"28","author":"Myers","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.02.010_BIB5","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/0016-5085(95)90691-6","article-title":"Delivery and fate of oral mesalamine microgranules within the human small intestine","volume":"108","author":"Layer","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB6","first-page":"479","article-title":"Intestinal metabolism and transport of 5-aminosalicylate","volume":"27","author":"Zhou","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.gtc.2004.02.010_BIB7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2036.2003.01408.x","article-title":"The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis","volume":"17","author":"Sandborn","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2004.02.010_BIB8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0016-5085(82)80075-9","article-title":"5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans","volume":"83","author":"Rasmussen","year":"1982","journal-title":"Gastroenterology"},{"issue":"5 Pt 1","key":"10.1016\/j.gtc.2004.02.010_BIB9","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/cpt1975185part1514","article-title":"Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease","volume":"18","author":"Das","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.gtc.2004.02.010_BIB10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/00365528209182073","article-title":"Sulfasalazine intolerance: a retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease","volume":"17","author":"Nielsen","year":"1982","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB11","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/BF01296907","article-title":"Sulfasalazine: adverse effects and desensitization","volume":"28","author":"Taffet","year":"1983","journal-title":"Dig Dis Sci"},{"issue":"4 Pt 2","key":"10.1016\/j.gtc.2004.02.010_BIB12","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/0016-5085(79)90386-X","article-title":"National Cooperative Crohn's Disease Study: adverse reactions to study drugs","volume":"77","author":"Singleton","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB13","first-page":"27","article-title":"Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease","volume":"6","author":"Korelitz","year":"1984","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB14","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1001\/jama.239.24.2590","article-title":"Sulfasalazine toxic reactions: hepatitis, fever, and skin rash with hypocomplementemia and immune complexes","volume":"239","author":"Mihas","year":"1978","journal-title":"JAMA"},{"key":"10.1016\/j.gtc.2004.02.010_BIB15","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/00007611-197809000-00031","article-title":"Granulomatous hepatitis associated with salicylazosulfapyridine therapy","volume":"71","author":"Callen","year":"1978","journal-title":"South Med J"},{"key":"10.1016\/j.gtc.2004.02.010_BIB16","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/BF01072475","article-title":"Azulfidine- (sulfasalazine-) induced hepatic injury","volume":"23","author":"Kanner","year":"1978","journal-title":"Am J Dig Dis"},{"key":"10.1016\/j.gtc.2004.02.010_BIB17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1378\/chest.101.4.1033","article-title":"Sulfasalazine-induced pulmonary disease","volume":"101","author":"Hamadeh","year":"1992","journal-title":"Chest"},{"key":"10.1016\/j.gtc.2004.02.010_BIB18","first-page":"614","article-title":"Sulfasalazine-induced lupus syndrome in a patient with Crohn's disease","volume":"77","author":"Carr-Locke","year":"1982","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB19","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/archinte.140.8.1122a","article-title":"Selective erythroid and magakaryocytic aplasia after sulfasalazine administration","volume":"140","author":"Davies","year":"1980","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.gtc.2004.02.010_BIB20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/gut.28.5.613","article-title":"Salicylate induced exacerbation of ulcerative colitis","volume":"28","author":"Chakraborty","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.02.010_BIB21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/00365528709078600","article-title":"Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine","volume":"22","author":"Rao","year":"1987","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB22","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/gut.28.11.1474","article-title":"Influence of olsalazine on gastrointestinal transit in ulcerative colitis","volume":"28","author":"Rao","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.02.010_BIB23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/0016-5085(88)90172-2","article-title":"Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro: comparison with sulfasalazine and 5-aminosalicylic acid","volume":"95","author":"Pamukcu","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB24","first-page":"724","article-title":"Chronic interstitial nephritis and mesalazine: 3 new cases?","volume":"22","author":"Brouillard","year":"1998","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB25","first-page":"265","article-title":"Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease","volume":"49","author":"Calvino","year":"1998","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1365-2036.2002.01155.x","article-title":"Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis","volume":"16","author":"Mahmud","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2004.02.010_BIB27","first-page":"A991","article-title":"Renal safety of long-term mesalamine therapy in inflammatory bowel disease (IBD)","volume":"112","author":"Hanauer","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB28","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1046\/j.1365-2036.1996.92264000.x","article-title":"Adverse events in patients treated with 5-aminosalicyclic acid: 1993\u20131994 pharmacovigilance report for Pentasa in France","volume":"10","author":"Marteau","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2004.02.010_BIB29","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/0003-4819-118-7-199304010-00009","article-title":"Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis","volume":"118","author":"Sutherland","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2004.02.010_BIB30","article-title":"Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis","volume":"2","author":"Sutherland","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gtc.2004.02.010_BIB31","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000543","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","volume":"1","author":"Sutherland","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gtc.2004.02.010_BIB32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0016-5085(98)70627-4","article-title":"Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group","volume":"114","author":"Green","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB33","first-page":"1398","article-title":"A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis","volume":"97","author":"Levine","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB34","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1111\/j.1572-0241.2002.07103.x","article-title":"Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis","volume":"97","author":"Pruitt","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB35","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1111\/j.1572-0241.2002.07092.x","article-title":"Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis","volume":"97","author":"Sandborn","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB36","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1136\/gut.30.10.1354","article-title":"Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial","volume":"30","author":"Feurle","year":"1989","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.02.010_BIB37","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000543","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","volume":"1","author":"Sutherland","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gtc.2004.02.010_BIB38","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1365-2036.1999.00482.x","article-title":"A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial","volume":"13","author":"Gionchetti","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2004.02.010_BIB39","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1572-0241.2000.01940.x","article-title":"A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis","volume":"95","author":"Cohen","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gut.40.6.775","article-title":"Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis","volume":"40","author":"Marshall","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.02.010_BIB41","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1023\/A:1017987229718","article-title":"Role of 5-Aminosalicylic Acid (5-ASA) in treatment of inflammatory bowel disease. A Systematic Review","volume":"47","author":"Gisbert","year":"2000","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.gtc.2004.02.010_BIB42","first-page":"A739","article-title":"A controlled randomized trial of beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (1 g) versus the combination of both as retention enemas in active distal ulcerative colitis","volume":"106","author":"Mulder","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004836-199504000-00022","article-title":"5-Aminosalicylic acid enemas to maintain remission in left-sided ulcerative colitis: a meta- and economic analysis","volume":"20","author":"Trallori","year":"1995","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB44","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/gut.42.6.761","article-title":"What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?","volume":"42","author":"Riley","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.02.010_BIB45","first-page":"1188","article-title":"Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group","volume":"88","author":"Hanauer","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB46","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.02.010_BIB47","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/jcgh.2003.50006","article-title":"The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine","volume":"1","author":"Kruis","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB48","first-page":"1143","article-title":"Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study","volume":"92","author":"d'Albasio","year":"1997","journal-title":"Am J Gastroenterol"},{"issue":"4 Pt 2","key":"10.1016\/j.gtc.2004.02.010_BIB49","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB51","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0016-5085(93)90337-C","article-title":"Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group","volume":"104","author":"Singleton","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB52","unstructured":"Hanauer S, Stromberg R. Clin Gastroenterol Hepatol, in press."},{"key":"10.1016\/j.gtc.2004.02.010_BIB53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000199279","article-title":"Effect of a slow-release 5\u2032-aminosalicylic acid preparation on disease activity in Crohn's disease","volume":"33","author":"Saverymuttu","year":"1986","journal-title":"Digestion"},{"key":"10.1016\/j.gtc.2004.02.010_BIB54","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00004836-199412000-00003","article-title":"A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis","volume":"19","author":"Tremaine","year":"1994","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB55","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0016-5085(99)70172-1","article-title":"Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial","volume":"116","author":"Prantera","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB56","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1056\/NEJM199808063390603","article-title":"A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group","volume":"339","author":"Thomsen","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.02.010_BIB57","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1365-2036.2003.01661.x","article-title":"Review article: mild to moderate Crohn's disease\u2013defining the basis for a new treatment algorithm","volume":"18","author":"Sandborn","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2004.02.010_BIB59","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1572-0241.1999.935_q.x","article-title":"A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID)","volume":"94","author":"Colombel","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/gut.18.1.69","article-title":"Sulphasalazine in asymptomatic Crohn's disease: a multicentre trial","volume":"18","author":"Lennard-Jones","year":"1977","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.02.010_BIB61","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0016-5085(93)90411-5","article-title":"Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID)","volume":"104","author":"Gendre","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB62","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1053\/gast.1996.v110.pm8608877","article-title":"Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives","volume":"110","author":"Modigliani","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB63","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2036.1990.tb00449.x","article-title":"Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group","volume":"4","author":"International Mesalazine Study Group","year":"1990","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2004.02.010_BIB64","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF01308338","article-title":"Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease","volume":"37","author":"Brignola","year":"1992","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gtc.2004.02.010_BIB65","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0016-5085(92)90822-G","article-title":"Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease","volume":"103","author":"Prantera","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB66","first-page":"692","article-title":"Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis","volume":"89","author":"Messori","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB67","first-page":"2116","article-title":"Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis","volume":"89","author":"Steinhart","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB68","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/gast.1997.v113.pm9352848","article-title":"Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables","volume":"113","author":"Camma","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB69","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","article-title":"Predictability of the postoperative course of Crohn's disease","volume":"99","author":"Rutgeerts","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB70","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1572-0241.2000.02000.x","article-title":"Medical therapy to reduce postoperative Crohn's disease recurrence","volume":"95","author":"Achkar","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB71","first-page":"847","article-title":"The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease: a controlled double-blind trial","volume":"77","author":"Wenckert","year":"1978","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB72","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000199850","article-title":"Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial","volume":"42","author":"Ewe","year":"1989","journal-title":"Digestion"},{"key":"10.1016\/j.gtc.2004.02.010_BIB73","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/00365521.1976.12097167","article-title":"Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease","volume":"11","author":"Bergman","year":"1976","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB74","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0016-5085(00)70208-3","article-title":"Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI","volume":"118","author":"Lochs","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB75","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1572-0241.2001.03671.x","article-title":"Management of Crohn's disease in adults","volume":"96","author":"Hanauer","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.010_BIB76","first-page":"CD000301","article-title":"Corticosteroids for maintaining remission of Crohn's disease","author":"Steinhart","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gtc.2004.02.010_BIB77","first-page":"1","article-title":"Budesonide for maintenance of remission in Crohn's disease (Cochrane Review)","author":"Simms","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gtc.2004.02.010_BIB78","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.010_BIB79","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn's disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.02.010_BIB80","first-page":"1343","article-title":"Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group","volume":"88","author":"Hanauer","year":"1993","journal-title":"Am J Gastroenterol"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855304000251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855304000251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T23:38:55Z","timestamp":1625787535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855304000251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0889855304000251"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2004.02.010","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}